Former Alchemia (ASX:ACL) chief Charles Walker has taken the role of Imugene (ASX:IMU) CEO, to help lead the company's efforts to commercialise HER-Vaxx in gastric cancer. [ + ]

One of the biggest problems for conservation today is that it ignores 95% of all known species on Earth. Could a company ignore that proportion of its clients or a government so many of its voters? So why does this problem exist in conservation? [ + ]

​Two separate studies into the oilseed crop canola are providing vital information that will help improve crop yields. An international genome study has shed light on the historical origins of canola, while researchers have also discovered the key to understanding what makes Australian canola flower earlier than its Canadian and European counterparts. [ + ]

Regeneus (ASX:RGS) and Cryosite (ASX:CTE) have agreed to share technology and expertise in the area of stem cell products for human applications. [ + ]

Sirtex Medical (ASX:SRX) has posted a 30.6% increase in profit for FY14, as dose sales of its SIR-Spheres liver cancer treatment reached a record high. [ + ]

Researchers from the University of Utah have discovered a method for turning a small, $40 needle into a 3D microscope capable of taking images up to 70 times smaller than the width of a human hair. [ + ]

The upcoming Annual Scientific Conference of the Australasian Association of Clinical Biochemists (AACB) will focus on Clinical Biochemistry Supporting P4 Medicine - the four 'Ps' representing personalised, predictive, preventive and participatory. [ + ]

The value of an artwork can vary by orders of magnitude if its provenance can be established; increasingly, science is coming to the aid of curators to prove provenance. [ + ]

Innate Immunotherapeutics (ASX:IIL) announced that WANRI - lead site for its phase IIb trial of MIS416 in secondary progressive multiple sclerosis - has been cleared to start recruiting patients. [ + ]

QRxPharma (ASX:QRX) has ceased development of dual-opioid drug MoxDuo, after the board decided that the cost of additional trials sure to be required for US approval could not be justified. [ + ]

This is a transcript of the 2014 Jack Beale Lecture on the Global Environment, hosted at the University of New South Wales. [ + ]

Industry Minister Ian Macfarlane let his discretion slip this week in a speech to the Queensland Media Club when foreshadowing an upcoming report on research funding and competition. Distancing himself from the awarding of funding based on prior researcher publications, he signalled a distinctly different approach that is likely to inform policy in the near future. [ + ]

CSL (ASX:CSL) has reported an 8% growth in FY14 profit, despite the impact of a legal settlement and a decline in sales at its bioCSL division. [ + ]

Additive manufacturing and 3D printing technology have a lot to offer makers of biomedical devices. [ + ]

The Global Alliance for Genomics and Health has announced a new application programming interface that will allow DNA data providers and consumers to better share information and work together on a global scale. [ + ]